GENE THERAPY FOR HEPATITIS C INFECTION--CHRONIC INFECTIOUS DISEASE MODEL

大约一年前，一项新的倡议开始发展起来 全面的研究和开发计划，以满足 挑战未来输血服务的需求。作为我们的一部分 服务责任，我们将被要求提供最先进的 向其他界别提供品质支援及谘询 研究所。补充我们在病毒方面的专业知识和经验 肝炎研究，为了有选择性和专注，我们选择了 将这个新的研发计划建立在传染病模型上。至 研究基因治疗作为人类治疗方法的可能性 丙型肝炎感染和发展这一方法作为一种模型 针对慢性传染病，我们设立了以下目标：(A) 建立一种功能可测量的基因表达模型 使用病毒介导的基因传递系统的造血细胞 丙型肝炎病毒(丙型肝炎病毒)基因；(B)发展血统特异性 在造血细胞中表达丙型肝炎病毒基因；。(C) 通过以下方式证明谱系特异性基因表达的有效性 用CTL试验和肿瘤杀伤试验进行功能评估 针对丙型肝炎病毒特异性表位；以及，(D)建立血统- 特异性基因表达作为一种治疗慢性阻塞性肺疾病的手段 丙型肝炎病毒感染。在过去的一年里，在老鼠模型中，我们有 评估病毒基因传递系统并建立CTL检测 抗丙型肝炎病毒核心蛋白和包膜蛋白。

About a year ago a new initiative started to develop a comprehensive research and development program to meet the challenging demand of future transfusion services. As part of our service responsibility, we will be required to provide state-of-the-art quality supports and consultation to the other sectors within the institute. To complement our expertise and experience in viral hepatitis research, and to be selective and focused, we chose to build this new R&D program on an infectious disease model. To investigate gene therapy as a therapeutic approach for human hepatitis C infection and to develop this approach as a model for chronic infectious diseases, we have set up the following goals: (a) to establish a functionally measurable gene expression model in hematopoietic cells using a virally-mediated gene delivery system for the hepatitis C virus (HCV) gene; (b) to develop lineage-specific gene expression in hematopoietic cells for HCV genes; (c) to demonstrate the efficacy of lineage-specific gene expression by functional assessment with CTL assays and tumor-killing assays directed to HCV-specific epitopes; and, (d) to establish lineage- specific gene expression as a therapeutic modality against chronic HCV infection. In the past year, in a mouse model, we have evaluated a viral gene delivery system and established CTL assays against HCV core and envelope proteins.